Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
There is a critical need for safe and effective drugs for COVID‐19. Only remdesivir has received authorization for COVID‐19 and has been shown to improve outcomes but not decrease mortality. However, the dose of remdesivir is limited by hepatic and kidney toxicity. ACE2 is the critical cell surface...
Saved in:
| Published in: | EMBO molecular medicine Vol. 13; no. 1; pp. e13426 - n/a |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
11.01.2021
EMBO Press John Wiley and Sons Inc Springer Nature |
| Subjects: | |
| ISSN: | 1757-4676, 1757-4684, 1757-4684 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!